In reply
We agree that patients with non-STEMI who are at highest clinical risk would likely benefit from an early reperfusion strategy. However, patients with non-STEMI are heterogeneous and represent a wide spectrum of clinical risk and pathophysiologic features. These can range from a partially or completely occlusive thrombus to severe ischemia secondary to “supply-demand” mismatch. The benefits of an early reperfusion strategy would vary substantially for these different scenarios.